SNDX-5613

CAS No. 2169919-21-3

SNDX-5613 ( —— )

Catalog No. M23982 CAS No. 2169919-21-3

SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 88 In Stock
5MG 147 In Stock
10MG 259 In Stock
25MG 514 In Stock
50MG 737 In Stock
100MG 1017 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SNDX-5613
  • Note
    Research use only, not for human use.
  • Brief Description
    SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM).
  • Description
    SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias.
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Histone Demethylase
  • Recptor
    Menin-MLL
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2169919-21-3
  • Formula Weight
    630.8
  • Molecular Formula
    C32H47FN6O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)
  • SMILES
    O=C(C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)N(C(C)C)CC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
molnova catalog
related products
  • LSD1-IN-7 benzenesul...

    LSD1-IN-7 benzenesulfonate is a potent and orally active inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity.

  • NCGC00244536

    NCGC00244536 is a potent KDM4B inhibitor (IC50: 10 nM).NCGC00244536 effectively inhibits AR-positive cell lines.

  • Vafidemstat

    Vafidemstat is a novel potent, selective lysine-specific histone demethylase (LSD1) inhibitor.